Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality

Autor: M. Monreal MD, PhD, G. Agnelli PROF, L. H. Chuang PhD, A. T. Cohen MBBS, MSc, MD, FRACP, FESC, P. D. Gumbs PhD, R. Bauersachs MD, P. Mismetti MD, A. K. Gitt, S. Kroep PhD, S. N. Willich MD, B. Van Hout PROF
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
Druh dokumentu: article
ISSN: 1938-2723
10760296
DOI: 10.1177/1076029619883946
Popis: Objectives: Deep vein thrombosis (DVT) is a major health-care burden in Europe, but exact estimates are lacking. This study reports results from the PREFER venous thromboembolism (VTE) study concerning health-related quality of life (HrQoL) and mortality of patients with DVT. Methods: PREFER VTE was a prospective, observational study, conducted in 7 European countries, designed to provide data concerning treatment patterns, resource utilization, mortality, and QoL. First-time or recurrent patients with DVT were followed at 1, 3, 6, and 12 months. Health-related QoL—as measured by the EuroQoL 5-Dimension 5-Level instrument ( EQ-5D-5L)—was analyzed using Tobit regression with repeated measures, assessing the impact of baseline characteristics stratified by cancer activity. Mortality was analyzed using logistic regression. Results: At baseline, patients with DVT had a 0.14 lower EQ-5D-5L index score (0.72 for total sample) compared to the reference UK population (0.85). The EQ-5D-5L index score improved from baseline to 12 months in patients with active cancer (from 0.70 to 0.79) and those without (0.72-0.87); 7.3% died within a year, a 5.2% excess mortality compared to the age- and gender-adfjusted general population. The 12-month mortality rate of DVT varied between 2.9% in the pooled data from Germany, Switzerland, or Austria and 15.4% in Italy. Furthermore, the mortality rate differed between patients with active cancer and those without (42.9% vs 4.7%). Conclusions: Deep vein thrombosis is associated with a substantial burden of illness in terms of HrQoL at baseline, which following treatment normalizes after 12 months and has a significant mortality rate. In addition, active cancer has a significant impact on mortality and the HrQoL of patients with DVT.
Databáze: Directory of Open Access Journals
Externí odkaz: